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Introduction: Approximately 20% of patients with colorectal cancer have metastases at the time of
presentation. Such patients are often offered systemic chemotherapy but debate continues as to whether
these patients beneﬁt from resection of the primary tumour. We describe our ten years experience of
managing the primary tumours in patients with stage IV colorectal cancer. The aim of this study was to
describe the overall survival of patients undergoing surgery in these circumstances and to determine
whether any prognostic indicators could be identiﬁed.
Patients & methods: 920 consecutive patients presenting with stage IV colorectal cancer disease were
identiﬁed from the Leicester Colorectal Cancer database. Patients undergoing resection of the primary
tumour (Resection Group) with the residual metastatic disease were compared to those patients who
had not their primary tumour excised (Non-Resection Group). Various different variables in two groups
were compared by using Mann-Whitney U test. KaplaneMeier survival analysis and log-rank test were
used to compare the overall survivals. Univariate analysis was performed for each group to elicit the
signiﬁcant prognostic factors whereas Cox regression model was used to identify the independent
predictors of overall survival.
Results: The KaplaneMeier survival analysis of two groups showed prolonged survival for Resection
Group compared to the Non-Resection Group (median; 14.5 Vs 5.83 months, p ¼ <0.005). The multi-
variate analysis of different survival predicting variables, revealed the resection of the primary tumour as
an independent predictor of overall survival (p < 0.001). The univariate analysis of resection group
identiﬁed age at presentation, tumour site, tumour stage (pT), lymph nodal stage (pN), complete
histological resection, tumour ﬁxity, ASA grade, mode of surgery, post-operative chemotherapy and sites
of metastasis as signiﬁcant factors (p < 0.05) for survival prediction. When these factors were used in
Cox-Regression model, only the age at presentation (p ¼ 0.001), tumour ﬁxity (p ¼ 0.012) and lymph
nodal involvement (p ¼ 0.042) were independent predictors for overall survival. Treatment with post-
operative chemotherapy and a smaller volume of liver metastases were associated with prolonged
survival (p < 0.05).
Conclusions: Surgical resection of primary tumour for stage IV colorectal cancers is associated with
prolonged survival for selected patients. Age at presentation, extent of liver involvement, tumour ﬁxity
and ASA grade can help to decide the patients who will beneﬁt from surgery.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Colorectal cancer (CRC) is the third most common malignant
neoplasm worldwide1 and the fourth leading cause of cancer-: þ44 116 2523274.
am), akelkara@hotmail.com
), john.jameson@uhl-tr.nhs.
ciates Ltd. Published by Elsevier Ltrelated deaths worldwide (World Health Organization, 2008). It is
a signiﬁcant health problem in the UK, accounting for 28.3 deaths
per 100,000 in men and 24.2 deaths per 100,000 in women in
2007.2 Around 100 new cases of colorectal cancer are diagnosed
each day in the UK; around two-thirds in the colon and one-third in
the rectum. The survival and prognosis of CRC depends on the stage
of the tumour at the time of detection and unfortunately more than
20% of patients with cancer have distant spread of their disease
(stage IV) at the time of diagnosis.3,4 Despite signiﬁcant investment
and advances in the management of cancer, the overall survival ford. All rights reserved.
Table 1
Comparison of demographics, clinical and tumour characteristics of patients in the colorectal cancer Resection and Non-Resection Groups.
Demographics Characteristics Resection n (%) Non-resection n (%) p-values
Patient (n) Number of patients 366 281 NS
Age Median (range) years 70 (27e92) 72 (31e96) NS
Gender Male 198 (54.1) 219 (78.0) <0.05
Female 168 (45.9) 62 (22.0)
Site of tumour Right colonic 144 (39.3) 65 (23.2) <0.05
Left colonic 114 (31.1) 97 (34.5)
Rectal 108 (29.5) 119 (42.3)
Tumour ﬁxity Fixed 34 (9.2) 25 (8.9) <0.05
Mobile 135 (36.9) 02 (0.7)
Tethered 73 (19.9) 09 (3.2)
Unknown 124 (33.9) 245 (87.1)
Detection of metastasis Radiology imaging 232 (63.4) 242 (86.1) <0.05
Radiology imaging & histology 10 (2.7) 11 (3.9)
Radiology imaging & surgery 16 (4.4) 05 (1.8)
Surgery  histology 108 (29.5) 23 (8.2)
Distant metastasis site Liver e solitary 55 (15.0) 12 (4.8) <0.05
Liver e multiple unilobar 56 (15.3) 13 (4.6)
Liver e multiple unilobar and lungs 05 (1.4) 02 (0.7)
Liver e multiple bi-lobar 130 (35.5) 111 (39.5)
Liver e multiple bilobar and lungs 16 (4.4) 42 (14.9)
Multi-organ excluding lungs 19 (5.2) 15 (5.3)
Lungs only 12 (3.8) 20 (7.1)
Peritoneal spread 49 (13.4) 44 (15.6)
Extra-mesenteric lymph nodes 37 (10.1) 13 (4.6)
Oncology treatment Radiotherapy 20 (5.5)a 25 (8.9) NS
Chemotherapy 21 (5.7)b 101 (35.9) <0.05
231 (63.1)c
ASA score ASA e II 213 (58.2) 47 (16.7) <0.05
ASA e III 101 (27.6) 37 (13.2)
ASA e IV 19 (5.2) 12 (4.3)
Unknown 33 (9.0) 185 (65.8)
Mode of surgery Urgent 112 (30.6) N/A N/A
Not recorded 14 (3.8)
Routine 240 (66.5)
a Pre-operative radiotherapy.
b Pre-operative chemotherapy.
c Post-operative chemotherapy.
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years with 5-year survival at almost 90% for stage I cancers to
5%e15% for stage IV disease.2,5,6 Approximately 10e25% of patients
with stage IV cancer present with metastatic disease that can be
resected surgically.7 Such low rates of resectability are attributed to
the heterogeneous nature of metastasis, severity of presenting
symptoms, general health of persons and well-deﬁned indications
for resection of metastasis in liver and lungs.8,9 The management of
patients with stage IV colorectal cancer is a matter of ongoing
controversy, which is further complicated by the introduction of
effective chemotherapy and targeted therapy regimens that have
been proven to result in resectable metastatic disease in many
patients. This paper aims to describe the outcomes of such surgeryTable 2
Comparison of mean and median survivals of Resection and Non-Resection Groups.
Operation Mean survival time (months)
Survival
(months)
Std. error 95% Conﬁdence int
Lower
bound
U
b
Resection 24.6 1.780 21.05 2
Non-Resection 9.3 0.56 8.52 1
Overall 21.5 1.50 18.55 2in a population of patients presenting with metastatic (stage IV)
colorectal cancers. To help in the decision making process for
individual patients, this study aims to identify different variables
predicting overall survival for patients undergoing resection of
their primary tumours without the resection of their metastases.2. Patients & methods
The University Hospitals of Leicester (UHL) Colorectal Cancer
Database, a prospective audit of patient outcomes, was examined
for all patients diagnosed with stage IV colorectal cancer at
presentation between January 1998 and December 2007.Median survival time (months)
erval Survival
(months)
Std. error 95% Conﬁdence interval
pper
ound
Lower
bound
Upper
bound
8.11 14.53 0.77 13.01 16.06
0.37 5.83 0.55 4.74 6.92
4.41 12.400 0.801 10.82 13.98
Fig. 1. KaplaneMeier survival curves comparing the overall survival of Resection and
Non-Resection Groups (p < 0.001).
Fig. 2. Comparison of yearly survivals associated with Resection and Non-Resection
Groups (p < 0.05).
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consultant surgeons, colorectal MDT (multidisciplinary team)
co-ordinators and the gastrointestinal cancer audit data analyst.
Those patients who had resection of their primary tumour with the
residual metastatic disease (Resection group) and those who had
not their primary tumour excised (Non-Resection Group) were
included in the study. Patients presenting with intractable
bleeding, malignant ascites, malignant pleural effusion, bowel
ﬁstulation, obstructive jaundice, intra-abdominal abscess, bowelTable 3
Clinical and tumour characteristics used for univariate and multivariate analysis of Non
survival ranges.
Criterion Characteristics n M
(
Gender Male 219
Female 62
Age at presentation (years) <50 27
51e60 39 1
61e70 61
71e80 84
>80 70
Tumour site Right colonic 65
Left colonic 97
Rectal 119
Tumour ﬁxity Fixed 25 1
Tethered 02
Mobile 09 1
Not recorded 245
ASA grade ASA II 47 1
ASA III 37
ASA IV 12
Not recorded 185
Chemotherapy No 180
Yes 101
Metastasis site Liver e solitary 12 1
Lungs only 20 1
Solitary liver & solitary lung 13 1
Liver e multiple unilobar 13
Liver e multiple bi-lobar 111
Liver e multiple bilobar & lungs 42
Multi-organ excluding lungs 15obstruction and/or bowel perforation were excluded from the
study. For the patients included in the study, the following
parameters were studied; age at presentation, gender, site of
primary tumour, ﬁxity of primary tumour, site of metastasis, mode
of detection of metastasis, ASA grade, mode of surgery and onco-
logical treatment. In the Resection group following additional
parameters were also studied; pre resection oncological treatment,
post resection oncological treatment, histo-pathological charac-
teristics of resected tumour, post-operative complications, 30 day
post-operative mortality and 90 day post-operative mortality.-Resection Group. Median survivals are tabulated with 95% conﬁdence intervals of
edian survival
months)
95% Conﬁdence
interval
Univariate
p-value
Multivariate
p-value
Lower
bound
Upper
bound
5.46 4.29 6.63 0.027 0.65
8.23 3.66 12.79
8.23 5.23 11.23 0.002 0.01
1.23 8.78 13.68
6.33 3.56 9.1
4.33 2.72 5.94
3.13 2.51 3.78
6.36 3.08 9.64 0.005 0.045
7.86 5.38 10.35
3.30 1.64 4.95
0.90 8.74 13.06 0.105 N/A
9.90 0.00 25.7
0.33 3.41 17.24
6.68 2.52 10.10
2.167 9.70 14.63 0.002 0.041
5.83 2.57 9.09
4.93 0.00 9.96
4.66 3.47 5.86
3.53 2.65 4.41 0.046 0.058
7.70 5.52 9.87
3.96 6.74 17.19 0.029 0.12
6.80 14.17 19.43
5.06 8.25 31.88
3.73 0.68 6.78
4.93 3.45 6.41
5.63 3.62 7.64
3.66 0.33 7.83
Table 4
Clinical and tumour characteristics used for univariate and multivariate analysis of Resection Group. Median survivals are tabulated with 95% conﬁdence intervals of survival
ranges.
Criterion Characteristics Number
(n)
Median survival
(months)
95% Conﬁdence
interval
Univariate
p-value
Multivariate
p-value
Lower
bound
Upper
bound
Gender Male 198 15.53 13.7 17.3 0.126 N/A
Female 168 13.33 11.0 15.7
Age at presentation (years) <50 30 28.9 14.2 43.7 <0.001 0.001
51e60 62 20.3 13.5 27.1
61e70 100 15.7 14.3 17.1
71e80 119 11.9 9.0 14.8
>80 55 6.76 2.5 11.0
Tumour site Right colonic 144 12.00 9.8 14.2 0.034 0.142
Left colonic 113 15.70 13.7 17 6
Rectal 108 16.63 12.2 21.1
Tumour stage (pT) T2 9 59.13 27.2 91.1 0.005 0.108
T3 128 16.56 14.4 18.7
T4 200 12.60 10.3 14.9
Nodal stage (pN) N0 61 20.6 15.5 25.7 0.05 0.042
N1 99 15.4 10.6 20.1
N2 176 13.7 12.0 15.4
N3 2 9.1
Unknown 28 10.3 2.8 17.9
Complete histological resection No 64 13.3 9.0 17.7 0.027 0.504
Yes 166 16.0 13.1 18.9
Tumour ﬁxity Fixed 34 10.26 2.9 17.6 0.01 0.012
Tethered 135 11.9 8.0 15.7
Mobile 73 16.5 12.9 20.0
Not recorded 124 14.4 10.7 18.1
ASA grade ASA II 213 16.36 14.1 18.6 <0.001 0.24
ASA III 101 9.36 5.5 13.3
ASA IV 19 1.60 0.0 04.2
Not recorded 33 12.10 9.3 14.9
Mode of surgery Routine 240 16.6 14.6 18.5 <0.001 0.058
Urgent 112 9.16 6.6 11.7
Not recorded 14 13.0 11.6 14.3
Post-operative chemotherapy No 135 3.7 1.2 06.1 <0.001 0.120
Yes 231 16.6 13.9 19.3
Peritoneal spread Yes 49 13.7 10.5 16.9 0.246 N/A
No 317 15.0 13.3 16.7
Distant metastasis site Liver e solitary 55 20.4 17.1 23.6 0.007 0.969
Liver e multiple unilobar 56 20.2 10.2 30.2
Liver e multiple unilobar & lungs 05 15.9 0.00 14.2
Liver emultiple bilobar 130 11.76 9.2 14.3
Liver e multiple bilobar & lungs 16 13.33 5.1 21.6
Multi-organ excluding lungs 19 13.63 7.4 19.8
Lungs only 12 20.96 14.4 27.5
Extra-mesenteric lymph nodes 37 10.60 4.6 16.6
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Hospital Information and Support System (HISS), from the Trent
Cancer Registry or by contacting the patient’s general practitioner.
3. Statistical analysis
The statistical evaluations were based on the date of the
patient’s death or the date of last follow-up. The inter-group
comparisons were made for the following parameters; age at
presentation, gender, site of primary tumour, ﬁxity of primary
tumour, site of metastasis, mode of detection of metastasis, ASA
grade and oncological treatment.
The two groups (Resection & Non-Resection) were compared by
using ManneWhitney U test. Survival curves were generated by
using KaplaneMeier survival analysis and the curves werecompared with the log-rank test. Univariate analyses were per-
formed for each group to identify the signiﬁcant prognostic factors
whereas Cox-regression model for survival analysis was used to
identify the independent predictors of survival. Differences were
considered statistically signiﬁcant at p < 0.05. All the statistical
tests were performed by using the SPSS 16.0 statistical software.
4. Results
Nine hundred and twenty patients registered in the database
with the diagnosis of stage IV colorectal cancer disease were
studied. 273 patients with malignant ascites (n ¼ 13), malignant
pleural effusion (n ¼ 3), bowel ﬁstulation (n ¼ 2), obstructive
jaundice (n ¼ 14), intra-abdominal abscess (n ¼ 4), intractable
bleeding (n ¼ 8), symptomatic bowel obstruction (n ¼ 156) and
Table 5
Peri-operative complications in 366 patients undergoing resection of primary
colorectal tumour. The post-operative complications were counted for each
complication type. 93 different major and 43 minor post-operative complications
were recorded for 118 (32%) patients.
Post-operative complications Number of
patients (n)
Patient
(%)
Major complications
Full thickness wound dehiscence 11 3
Intra-abdominal collections 11 3
Anastomotic leak 11 3
Intra-abdominal sepsis 08 2.2
Multi-organ failure 07 1.9
Arrthymia 07 1.9
Clostridium difﬁcle infection 05 1.4
Aspiration pneumonia & respiratory failure 05 1.4
Haemorrhage 05 1.4
Post-operative ileus 04 1.1
Broncho-pneumonia & respiratory failure 04 1.1
Acute renal failure 04 1.1
Myocardial infarction 03 0.8
MRSA infection 03 0.8
Left ventricular failure 03 0.8
Deep vein thrombosis 01 0.3
Splenic tear 01 0.3
Inter-loop ﬁstula 00 0.0
Minor complications
Chest infection 12 3.3
Wound infections without dehiscence 11 3
Urinary infection 06 1.6
Superﬁcial wound dehiscence 04 1.1
Complications of stoma 02 0.6
Urinary incontinence 02 0.6
Pleural effusion 02 0.6
Post-operative confusion 02 0.6
Urinary retention 01 0.3
Pressure sore 01 0.3
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patients (median age 70 years; M:F ¼ 1.17:1) underwent resection
of their primary colorectal tumour without the resection of their
synchronous metastases. A total of 281 (median age 72 years; M:
F ¼ 1.38:1) patients with stage IV colorectal cancer disease were
included in the Non-Resection Group. This group included patients
who received symptomatic and supportive treatment (n ¼ 168) orFig. 3. Percentage 30 day mortalities associated with Resection of Primary tumours in
patients with stage IV Colorectal Cancers. Figure also shows the comparison of 30-day
post-operative mortality for routine and urgent surgical procedures.chemotherapy (n ¼ 101). 45.55% (n ¼ 128) of the patients in this
group required surgical intervention [diverging stoma formation
(n¼ 101), colonic bypass (n¼ 7), colonic stent insertion (n¼ 20)] to
relieve the obstructing symptoms, they developed during the
course of their treatment for stage IV colorectal tumours. The
decision as to which treatment strategy used was made by
the multi-disciplinary team, based on the individual patient
circumstances. The patient and tumour characteristics for these
two groups of patients are summarized in Table 1.
4.1. Overall survival & ﬁve-year survivals
The median follow-up for 647 patients was 34 (10e122)
months. The multivariate analysis showed that one of the major
determinants of outcome was whether the primary tumour had
been resected or not (p< 0.001). When two groups were compared
with the KaplaneMeier survival analysis (Table 2 and Fig. 1) the
Resection group was associated with longer survival (median; 14.5
Vs 5.83 months, p  0.005).
4.1.1. Survival analysis for Non-Resection Group
Only one patient in Non-Resection Group was alive at three
years after the diagnosis. For this group one and two-year survivals
were 26.33% and 7.8% respectively. The univariate analysis of
different variables predicting the survival in the Non-Resection
Group identiﬁed the gender (p ¼ 0.027), ASA grade (p ¼ 0.002),
increasing age (p < 0.002), chemotherapy (p ¼ 0.046), tumour site
(p ¼ 0.05) and the metastasis site (p ¼ 0.029) as statistically
signiﬁcant factors. When used for Cox-Regression risk modelling
the increasing age (p¼ 0.01), tumour site (p¼ 0.045) and ASA grade
(p ¼ 0.041) were found to be the independent predictors of the
overall survival (Table 3). 36% of the patients in the Non-Resection
Group received chemotherapy. These patients beneﬁted from
higher survival when compared with those who did not receive
chemotherapy (median; 7.70 Vs 3.53 months, p ¼ 0.046). Patients
who received chemotherapy, those with ASA-grade 2 beneﬁted
with longer survivals when compared with those with ASA-grades
3 & 4 (median; 13.5 Vs 5.86 months, p < 0.05). However, patients
who did not receive chemotherapy, those with ASA-grade 2 still
beneﬁted with the longer survivals when compared with those
with ASA-grades 3 & 4. (Median; 11.9 Vs 3.96 months, p < 0.05)
4.1.2. Survival analysis for Resection group
Themedian time interval from detection of metastatic disease to
resection of primary tumour was 28 (0e482) days. For the Resec-
tion group the yearly survivals were: 56.5% (1 year); 24.3%
(2 years); 16.1% (3 years); 7.9% (4 years) and 3% (5 years). Fig. 2
compares the yearly survivals for Resection & Non-Resection
Groups. The KaplaneMeier analysis with log-rank test and the
univariate analysis of different variables in the Resection group
identiﬁed the age at presentation, primary tumour site, ASA grades,
mode of surgery, post-operative chemotherapy, sites of metastasis,
tumour stage (pT), lymph nodes stage (pN), histological
completeness of resection, ﬁxity of tumour, as signiﬁcant (p< 0.05)
factors for survival prediction (Table 4, Figs. 4 and 5). When these
factors were used in Cox-Regression model, only age at presenta-
tion (p ¼ 0.001), tumour ﬁxity (p ¼ 0.012) and nodal stage (pN)
(p ¼ 0.042) were independent predictors for overall survival.
Table 4 shows the median survivals and ranges of survivals (95%
conﬁdence interval) for different variables. Table 4 also shows the
p-values for variables identiﬁed in univariate and multivariate
analysis of survival.
Patients (n ¼ 49) with peritoneal metastasis had no signiﬁcant
differences (p¼ 0.246) in the overall survival (median survival: 13.7
Vs 15.0 months) when compared with the patients (n ¼ 317) who
M.I. Aslam et al. / International Journal of Surgery 8 (2010) 305e313310had no peritoneal involvement. In patients with multiple unilobar
liver metastasis the median survival was signiﬁcantly longer when
compared for patients with multiple bilobar liver metastasis
(median; 17.46 Vs 11.76 months, p < 0.05) (Table 5). This conﬁrms
the ﬁndings of previous studies reporting that the extent of the
liver involvement determines the overall survival of stage IV colo-
rectal cancers. The comparisons were made for the patients where
pathological ﬁndings for the primary tumour were available. The
Table 4 compares the overall survival by TN stage of the primary,
tumour ﬁxity and histological completeness of excision of the
primary. The median survival (28.9 months) was signiﬁcantly
prolonged for patients under the age of 50 years, continued to drop
with each decade, and reached 6.7 months for patients over the age
of 80 years. 237 (63%) of patients who underwent resection of the
primary tumour received post-operative chemotherapy. Patients
who received systemic therapy showed a survival advantage when
compared with patients who did not receive chemotherapy
(median; 16.6 Vs 3.7 months, p ¼ 0.001).
4.2. Post-operative morbidity
93 different major and 43 minor post-operative complications
were recorded for 118 (32%) patients in the Resection group. In the
Resection group, anastomotic leak, intra-abdominal collections, fullFig. 4. KaplaneMeier Survival curves for different variables in Resection group. The curves
shows higher survival for patients less than 50 years old and signiﬁcantly reduced survival fo
with higher survival (median; 16.6 Vs 13 months, p < 0.05) when compared with colonic
operative radiotherapy for rectal tumours. 4-c) 63% of the patients received post-operative sy
tumour for symptomatic patients on urgent basis was associated with shorter survival whethickness wound dehiscence, chest infections and superﬁcial
wound dehiscence contributed to nearly half of the post-operative
morbidities. The Table 5 further elaborates the frequencies of major
and minor complications.
4.3. Thirty day and ninety day post-operative mortality
This study reports the 30 days and 90 days post-operative
mortalities for Resection group as 7.6% and 15% respectively. Thirty-
day mortality for elective resection of the primary tumour (3.75%)
was signiﬁcantly lower (p < 0.05) when compared with the 30-day
mortality associated with the resections performed urgently
(16.96%) The Fig. 3 shows the comparison of 30-day post-operative
mortalities for urgent and routinely performed two surgical
procedures.
5. Discussion
In this selected group of patients these data have shown that
signiﬁcant survival can be obtained for patients undergoing surgery
in the presence of metastatic disease. Patients who underwent
surgical resection of primary tumour had clear survival advantage
(One year survival; 56.5% Vs 26.33%, two year survival; 24.3% Vs
7.86%) over those patients who did not have their tumours resectedwere compared with long-rank test. 4-a) Survival comparison for different age groups
r patients >80 years of age (p < 0.001). 4-b) Resection of rectal tumours was associated
tumours. Authors conclude that such survivals might have been contributed by pre-
stemic chemotherapy and beneﬁted from prolonged survival. 4-d) Resection of primary
n compared with routine elective resections (median; 9.16 Vs 16.6 months, p < 0.001).
Fig. 5. KaplaneMeir survival analysis for different histo-pathological features of resected primary colorectal tumours. 5-a) Survival curves are compared for patients who had
complete and incomplete histological excision of primary tumour. There is no signiﬁcant differences in the distribution of curves in ﬁrst 18 months, After 18 months the curves
diverge signiﬁcantly suggesting long term survivals beneﬁts associated with complete excision of primary tumours. 5-b) Operative ﬁndings of tumour ﬁxity or tethering to
surrounding structures were associated with comparatively shorter (p ¼ 0.01) survivals (median; 10.26 & 11.9 months) when compared with survivals of mobile tumours (median;
16.6 months). 5-c & 5-d) Histological staging from resected tumour (pT) and nodal involvement (pN) are used for comparison of overall survivals. Lower tumour burden (pT2) and
lesser extent of lymph nodes involvement (pN0 & pN1) are associated with prolonged survivals.
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these survival differences might have been contributed by the
signiﬁcant differences in two groups in terms of the distribution of
primary tumours, burden of metastatic disease, ASA score, gender
and chemotherapy. Nevertheless, these ﬁnds are in line with the
previously reported comparative studies of surgical resection and
non-resectional treatments for stage IV colorectal cancers.10e17
Although these studies have reported possible survival beneﬁts
with surgery, due to a lack of prospective clinical trials in this area,
no ﬁrm conclusions can be drawn with respect to whether resec-
tional surgery should be offered to this group of patients.
Conducting such a trial poses practical difﬁculties which have been
highlighted during discussions regarding a potential UK study of
Initial Surgery in Advanced Asymptomatic Colorectal cancer
(ISAAC). Some clinicians also believe that the surgical resection of
the primary tumour may delay or even preclude systemic therapy
and many patients may die from progressive systemic disease
before they develop any primary tumour speciﬁc complica-
tions.18,19 Nonetheless, the debulking surgery for other advancedmetastatic tumours such as ovarian20 and renal21,22 cancers have
shown signiﬁcant survival beneﬁts.
This study shows substantially prolonged survivals for younger
patients undergoing the resection of their primary tumour. The
decreased survivals associated with the increasing age have been
reported previously for stage IV colorectal cancers.9,12 The survival
analysis in this study has also elicited the increasing age as an
independent predictor of survival outcome for both Resection and
Non-Resection Groups. It is to be noted that 88% (n ¼ 49) of the
patients over the age of 80 years did not receive chemotherapy in
the Resection group on the basis that the oncologist felt that
chemotherapy would not be well tolerated, although the fact that
these patients had undergone a resection may have inﬂuenced this
decision. In this era in which the efﬁcacy of chemotherapy has so
dramatically improved,23 the treatment strategies for stage IV
colorectal cancers in elderly patients may need re-evaluation.24
This study may help promote a dialogue at multidisciplinary
meetings between the surgical team and medical oncologist to
establish a rationale for selection of treatment strategies and their
M.I. Aslam et al. / International Journal of Surgery 8 (2010) 305e313312timings for elderly patients. The study results also emphasize the
importance of the completeness of excision of the primary tumour
in stage IV colorectal cancer. Intra-operative ﬁndings about the
mobility of primary tumour in addition to the tumour stage and
completeness of resection should be considered at multidisci-
plinary meetings for selection of further treatment strategies.
In this study patients with solitary lung and liver metastasis did
not undergo resection of those metastases. This could be due to
patient choice or poor ﬁtness for the second operation. There is
now a trend towards resection of metastasis in lung and liver, and it
is possible to perform resectional surgery for synchronous multiple
metastasis in liver and/or lungs.25 This aggressive approach may be
justiﬁable in younger patients, who from this study tend to do
better, in attempt to gain useful prolonged survival. Such an
approach should be combined with systemic chemotherapy for
which evidence exists concerning the reduction in the number and
the volume of the metastasis in patients receiving systemic
chemotherapy in whom some initially unsuitable metastasis were
made suitable for resection.26,27
Previous studies have reported decreased survivals for patients
having peritoneal involvement with stage IV colorectal cancers.9,28
In the Resection group, forty nine patients had peritoneal metas-
tasis/involvement (Table 4). When compared with those with no
peritoneal involvement authors found no signiﬁcant differences in
survivals. This parameter was not a signiﬁcant variable on the
univariate and multivariate analysis, the important variables being
age, burden of primary tumour and extent of liver involvement.
This study has shown a 30-day post-operative mortality of 7.6%
for patients who underwent resection of the primary tumour. These
ﬁnds are in line with the 30 days post-operative mortality (0e9%)
reported in previous studies.11,14,16,17 Signiﬁcantly higher rates of
peri-operative morbidities (37%) are noted for this set of patients
albeit reports exist where such high morbidity from 20% to 50% has
been reported.9,10,14,29 Some studies11,13,16 have reported lower
rates of peri-operative morbidities (9%e18.7%) however the
number of patients in such studies were signiﬁcantly small when
compared to this study.
In this data set, 30% of the patients had the distant metastasis
detected at the time of surgery. Given the poor outcomes in patients
in whom resection is not possible, pre-operative cross-sectional
imaging is mandatory in this group of patients. This will allow
a more accurate assessment of whether resection of the primary
tumour can be achieved in patients presenting with metastatic
disease.
This study reports conﬁrms signiﬁcantly lower mortality for
elective resection of the primary tumour compared to urgent
surgery, a ﬁnding which also applies to patients without metastatic
disease. This is conﬁrmed in other studies of patients with stage IV
disease. (3%e6%), compared with the (20%e40%) operative
mortality for emergency resections.19,29,33 These ﬁndings raise the
question of whether a stent should be offered as a bridge to surgery
in advanced disease as well as in patients with non-metastatic
disease.30,31,32
Although this study has shown signiﬁcant survival after resec-
tional surgery,wehavenodata on thequality of life of thesepatients.
So, far no studies have been published where quality of life is
compared for operative and non-operative treatments for primary
tumour of stage IV colorectal cancers. In addition to the survival
advantage, the resection of the primary tumour in stage IV disease
helps in the prevention of symptoms arising from tumour burden
and carcinamatosis9,10 which can be considered a reasonable justi-
ﬁcation for surgical intervention. Reduction in other complications
such as intractable bleeding, obstruction and perforation has also
beennoted.11,18,38,39 Thismay inpart beexplainedby the lower levels
of cytokines and growth factors, leading to an improved immuneresponse and effective delivery of cytotoxic drugs to the residual
tumour seen in patients undergoing surgical debulking of the
primary tumour.34e37 Prospectivemeasurement of parameters such
as quality of life, number of hospital days, and interval from surgery
to initiation of chemotherapywould provide additional insights into
the rationale for surgery.
To conclude, the resection of primary tumour in stage IV colo-
rectal cancers is associated with prolonged overall survival in
selected patients. Careful selection of patients and electively
planned resections are associated with favourable outcomes.
Prospective studies evaluating the quality of life and symptoms
control need to be conducted to develop better insights into the
rationale of resection of primary tumours.
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